Medical Facilities Grew 10% Without Growing — and Nobody Showed Up to Ask
Revenue rose 9.8% on a 1.6% decline in surgical cases, the Sioux Falls headwind that dominated six straight calls has finally vanished, and the Q&A line was empty again
DR.TO · Earnings Call · 2026-11-12
Growth Without Growth
The headline out of Medical Facilities Corporation's Q3 reads clean. Revenue of $65.9 million, up 9.8% year over year. Income from operations to $11.2 million, up 17.3%. EBITDA to $14.1 million, up 13.5%. For a company with a market cap under CAD 200 million, that is a violent amount of operating leverage. But then read the volume line: “Total surgical case volume was down 1.6%, with inpatient, observation, and outpatient cases declining 3.4%, 2%, and 1.3% respectively.” — David Watson, Chief Financial Officer · 2026-11-12 Even stripping out the low-margin dental business, volumes were down 0.6%. So the entire 9.8% top line came from price and mix, not from more bodies on gurneys. That is not a scandal — it is the whole business model, and management says so plainly: “Our case mix, combined with a favorable payer mix, drove a 9.8% increase in facility service revenue and improved profitability in the quarter.” — Jason Redman · 2026-11-12 Higher-acuity orthopedics, more spine procedures, more pain management cases, and negotiated payer rate increases did the work. The catch: Case mix is the oldest sentence in this company's vocabulary. It was the single largest keyword gainer in the entire recorded history of these calls — momentum 194 back in 20212 — and it has resurfaced in 20231, 20241, 20242, 20252, 20262 and now tops the current list. It even had its own reversal quarter, the sharpest decliner on record in 20213. A genuinely strong quarter explained by a six-year-old mechanism is a quarter you should interrogate rather than celebrate. The honest reading is that MFC is a price-and-acuity story masquerading as a growth story, and it happens to be executing the price-and-acuity story well right now. The cost side moved in step: drugs and supplies up 12.2% on case mix, consolidated salaries up 7.7% on annual merit increases plus higher market driven compensation for anesthesia nurse practitioners. Note the anesthesia detail — contracted anesthesia staffing is the quiet structural cost creep in this model, and it has now shown up repeatedly.The Headwind That Vanished
The most revealing thing in this quarter is an absence. For six consecutive quarters, one keyword sat near the top of this company's list: Sioux Falls. It ranked first in 20252 with the highest momentum score of any term that quarter, and it recurred in 20251, 20241, 20242, 20232 and 20231. A year ago the CFO was still quantifying the damage: “If you look at the impact just on the revenue overall, it was certainly down about $3.9 million for the quarter.” — David N. T. Watson, Chief Financial Officer · 2025-08-08 And the CEO promised it was finished: “we think that the relocation impact is behind us.” — Jason P. Redman, Chief Executive Officer · 2025-08-08 He was right. In 20264, Sioux Falls does not appear at all. Neither does credit facility — a top-two theme in both 20252 and 20244 — because the corporate revolver was repaid in 2024. Neither does Arkansas surgical hospital, which ranked second as recently as 20262, nor "competitive environment." That is a real change in the story: the geographic and balance-sheet problems that framed every call from 2023 through mid-2025 have been resolved, and the narrative has shifted to mix and capital return. Investors who own this for the troubled-asset-recovery trade should notice the trade is largely done.The Buyback Is the Actual Thesis
With the operational noise cleared, the capital-return machine is what is left. “We fully utilized our normal course issuer bid purchase limit of approximately 1.8 million common shares by mid-July” — Jason Redman · 2026-11-12 — 1.7 million shares for $21.5 million through nine months, against a market cap near $193 million. Since the change in corporate strategy in Q3 2022, MFC has returned roughly CAD 219.6 million through a combination of NCIBs, substantial issuer bids and dividends. Stack that against the balance sheet: $70.8 million of consolidated cash, $60.7 million of it at the corporate level, and zero corporate debt. That corporate cash alone is a large fraction of the equity value. The company also has no obligation to deploy it quickly — the Oklahoma Spine Hospital sale in Q1 is what inflated the cash pile, and management has shown it will sit on proceeds rather than force a deal. On a $193 million cap, an NCIB of this size is materially accretive per share, which is a more reliable driver of returns than a 1-point mix improvement in any single quarter.There are no questions at this time. I'd now like to turn the call back over to Mr. Redman for final closing comments.